Related Experiment Videos

Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated

Daniela Giannessi1, Chiara Caselli, Silvia Del Ry

  • 1Research National Council (CNR) Institute of Clinical Physiology-Laboratory of Cardiovascular Biochemistry, Pisa 56124, Italy. danielag@ifc.cnr.it

Metabolism: Clinical and Experimental
|March 5, 2010
PubMed

Insights

Reduced adiponectin levels in dilated cardiomyopathy (DCM) patients correlate with abnormal lipid profiles and impaired myocardial blood flow. Lower adiponectin is linked to poorer coronary function and reduced HDL cholesterol in DCM.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Reduced plasma adiponectin is linked to adverse lipid profiles, impaired left ventricle (LV) function, and coronary atherosclerosis.
  • Dilated cardiomyopathy (DCM) is a condition affecting heart muscle function, often associated with metabolic and cardiovascular complications.

Purpose of the Study:

  • To investigate the relationship between plasma adiponectin levels and lipid profiles, LV function, and myocardial perfusion in DCM patients without overt heart failure.
  • To assess the association of adiponectin with coronary function and myocardial blood flow (MBF) in this patient cohort.

Main Methods:

  • Plasma adiponectin levels were measured in 55 DCM patients and 40 healthy controls.
  • Myocardial blood flow (MBF) was assessed using positron emission tomography and ¹³N-ammonia in a subset of patients.
  • Statistical analyses explored correlations between adiponectin, BMI, brain natriuretic peptide, HDL cholesterol, and MBF.

Main Results:

  • DCM patients exhibited significantly higher adiponectin levels compared to controls (10.9 vs 6.6 microg/mL).
  • Adiponectin inversely correlated with BMI and directly with HDL cholesterol and dipyridamole-induced MBF.
  • Lower adiponectin levels were associated with a higher total to HDL cholesterol ratio and reduced MBF reserve.

Conclusions:

  • Down-regulation of adiponectin and reduced HDL cholesterol may play a crucial role in impaired coronary function and myocardial perfusion in DCM.
  • Adiponectin levels serve as a potential biomarker for coronary microvascular dysfunction in DCM patients.
  • Further research is warranted to elucidate the therapeutic implications of modulating adiponectin in DCM.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...